In this third in our six-part series on prior authorization (PA) in Canada vs the U.S. we address the selective application of PA.
Featuring a conversation with Shanta Zurock, Director of Reimbursement with Innomar Strategies
Canada vs U.S. Prior Authorization Trends: The Role of Transparency and Communication in Prior Authorization
In our last blog we summarized the prior authorization (PA) reform experience in the United States […]
Since 2020, the conversation around improving the prior authorization process and experience has been gaining traction in Canada. Learn what Canadian stakeholders can take away from American developments.
Are you a physician, pharmacist, or other prescriber that has patients with a prescription for specialty medications? If you are, it’s likely that your patients have a prescription for a therapy or medication that requires prior authorization, and they probably have questions about it.
Do you represent a patient support/assistance program (PSP/PAP)? If you do, it’s likely that the patients you help have a prescription for a therapy or medication that requires prior authorization, and they probably have questions about it.
Advancements in medical research have yielded innovative medications in recent years and can significantly improve the lives of those living with migraine.
The Simplify Prior Authorization (SPA) initiative is pleased to announce that Innomar Strategies has joined the growing list of organizations working together for an improved prior authorization process.
Do you represent a private payer, such as an insurer or pharmacy benefit manager (PBM)? If so, you may be familiar with your organization’s role in the prior authorization process, a process that can be unique to each insurer, including claims criteria for approval.
Are you a plan sponsor or advisor? Do your plan members have claims for specialty drugs? If so, it’s likely that plan members have questions regarding the prior authorization process, a process common for the reimbursement of specialty drugs